Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III in Partial and Null Responders
Brief Summary: The purpose of this study is to demonstrate the efficacy of TMC435 in combination with peginterferon (PegIFN) + ribavirin (RBV) by means of establishing its non- inferiority compared to an approved regimen of telaprevir + PegIFN + RBV in patients who have previously failed PegIFN.


Options:
A: Arm Label: Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin (RBV) tablet | Arm Label: Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2b, Drug: Ribavirin (RBV) capsule | Arm Label: Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin (RBV) tablet | Arm Label: Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2b, Drug: Ribavirin (RBV) capsule | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet, Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule, Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet, Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule | Intervention Type: DRUG; Name: Peg-IFN-alfa-2a; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet, Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet | Intervention Type: DRUG; Name: Peg-IFN-alfa-2b; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule, Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule | Intervention Type: DRUG; Name: Ribavirin (RBV) tablet; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet, Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet | Intervention Type: DRUG; Name: Ribavirin (RBV) capsule; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule, Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule
B: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4, Group 5, Group 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4, Group 5, Group 6
C: Arm Label: SOF/VEL 12 Weeks; Type: EXPERIMENTAL; Interventions: Drug: SOF/VEL | Arm Label: SOF+RBV 24 Weeks; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Intervention Type: DRUG; Name: SOF/VEL; Assigned to Arm(s): SOF/VEL 12 Weeks | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF+RBV 24 Weeks | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+RBV 24 Weeks
D: Arm Label: TMC435/PR; Type: EXPERIMENTAL; Interventions: Drug: TMC435 | Arm Label: TVR/PR; Type: ACTIVE_COMPARATOR; Interventions: Drug: TVR | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): TMC435/PR | Intervention Type: DRUG; Name: TVR; Assigned to Arm(s): TVR/PR

Answer: D